Document is current
Any future updates will be listed below
-
Authors
Chang, Chin-Wei
Hsu, Wei-Fan
Tseng, Kuo-Chih
Chen, Chi-Yi
Cheng, Pin-Nan
Hung, Chao-Hung
Lo, Ching-Chu
Bair, Ming-Jong
Chen, Chien-Hung
Lee, Pei-Lun
Lin, Chun-Yen
Kuo, Hsing-Tao
Chen, Chun-Ting
Yang, Chi-Chieh
Huang, Jee-Fu
Tai, Chi-Ming
Hu, Jui-Ting
Lin, Chih-Lang
Su, Wei-Wen
Tsai, Wei-Lun
Huang, Yi-Hsiang
Cheng, Chien-Yu
Lin, Chih-Lin
Wang, Chia-Chi
Yang, Sheng-Shun
Mo, Lein-Ray
Chen, Guei-Ying
Chang, Chun-Chao
Wang, Szu-Jen
Huang, Chia-Sheng
Hsieh, Tsai-Yuan
Lin, Chih-Wen
Lee, Tzong-Hsi
Chong, Lee-Won
Huang, Chien-Wei
Chang, Shiuh-Nan
Tsai, Ming-Chang
Hsu, Shih-Jer
Kao, Jia-Horng
Liu, Chun-Jen
Liu, Chen-Hua
Lin, Han-Chieh
Tsai, Pei-Chien
Yeh, Ming-Lun
Huang, Chung-Feng
Dai, Chia-Yen
Chuang, Wan-Long
Yu, Ming-Lung
Peng, Cheng-Yuan
-
Funding
Funding for this research was provided by:
National Science and Technology Council (MOST111-2314-B-039-061-MY3)
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 25 May 2024
First Online: 4 July 2024
Declarations
:
: Ming-Lung Yu received research support from Abbott, BMS, Gilead, and Merck and served as a consultant of Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, and Roche and a speaker of Abbvie, Abbott, BMS, Gilead, Merck, and IPSEN. Cheng-Yuan Peng has served as an advisory committee member for Abbvie, Bristol-Myers Squibb, Gilead, and Merck Sharp & Dohme. All other co-authors have no conflicts of interest to declare.
